The effects of firocoxib on cauterity disbudding pain and stress responses in preweaned dairy calves

M. L. Stock,* S. T. Millman,† L. A. Barth,‡ N. K. Van Engen,† W. H. Hsu,* C. Wang,† R. Gehring,§ R. L. Parsons,† and J. F. Coetzee†1

*Department of Biomedical Sciences,
†Veterinary Diagnostic and Production Animal Medicine, and
‡Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames 50010
§Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan 66506

ABSTRACT

Perioperative analgesic effects of oral firocoxib following cauterity disbudding were investigated in preweaned calves. Twenty Holstein calves approximately 4 to 6 wk old received a single oral dose of firocoxib, a nonsteroidal antiinflammatory, at 0.5 mg/kg (n = 10) or placebo (n = 10) in a randomized controlled clinical trial. Responses, including ocular temperature determined by infrared thermography, pressure algometry measuring mechanical nociception threshold, and heart rate, were evaluated at 2, 4, 7, 8, and 24 h after cornual nerve block and cauterity disbudding. Blood samples were collected over 96 h and analyzed for plasma cortisol and substance P concentrations by RIA. Additionally, ex vivo prostaglandin E2 concentrations were determined over a 72-h study period using an enzyme immunoasay. Data were analyzed using a linear mixed effects model with repeated measures. An inhibition of ex vivo prostaglandin E2 synthesis was observed from 12 to 48 h following disbudding in calves treated with firocoxib. Cautery disbudding was associated with an increased nociception for the duration of sampling (24 h). During the initial 24-h period following disbudding, no difference in response between treatment groups was noted. Following 24 h, mean cortisol concentrations diverged between the 2 study groups with placebo-treated calves having increased cortisol concentrations at approximately 48 h after disbudding. Furthermore, the overall integrated cortisol response as calculated as area under the effect curve tended to be reduced in firocoxib-treated calves. The prolonged effects of cauterity dehorning require further investigation. Moreover, the effect of firocoxib on cortisol reduction observed in this study requires additional exploration.

Key words: welfare, disbudding, dehorning, nonsteroidal antiinflammatory, firocoxib

INTRODUCTION

Dehorning or disbudding cattle is a management procedure commonly performed on nearly 95% of US dairy operations (USDA, 2010). Horns or horn buds are primarily removed to accommodate production practices and prevent economic loss due to carcass bruising. Many techniques have been described, with the use of a hot iron reported to be the most commonly employed method in the United States (USDA, 2010). Although the AVMA (2012) supports methods to minimize pain and distress associated with disbudding and dehorning, methods to evaluate this response can be challenging given the need to use indirect measures to assess an affect state.

Behavioral, physiologic, and neuroendocrine changes have been reported following disbudding or dehorning (Stafford and Mellor, 2005; Stock et al., 2013). These observed and reported responses are frequently interpreted as being associated with pain and distress (McMeekan et al., 1998; Faulkner and Weary, 2000; Stewart et al., 2008; Heinrich et al., 2010). More specifically, indirect measures, such as changes in the hypothalamic-pituitary-adrenal axis activation resulting in cortisol release (McMeekan et al., 1998), mechanical nociception threshold (Heinrich et al., 2010), autonomic nervous system response (Stewart et al., 2008), and behavior (Faulkner and Weary, 2000), have been previously used to assess the pain and distress associated with disbudding in calves. The concurrent evaluation of several indices may improve the assessment of pain and distress in animals due to individual response variations (Molony and Kent, 1997).

As a consequence of disbudding or dehorning, acute changes in cortisol release (McMeekan et al., 1998), local nociception (Heinrich et al., 2010), ocular temperature and heart rate (Stewart et al., 2008), and head shakes...
and ear flicks (Faulkner and Weary, 2000; Stilwell et al., 2009) are reported. Local anesthetics have been useful in mitigating these acute effects following removal of the horns or horn buds (McMeekan et al., 1998; Stewart et al., 2008; Stilwell et al., 2009); however, these local anesthetics typically demonstrate only temporary reduction of these observed responses once the local anesthetic is no longer effective (Doherty et al., 2007; Heinrich et al., 2009; Allen et al., 2013).

Subsequent to the initial tissue damage involved with horn removal, continued cortisol and behavioral changes are observed, which may be due to inflammation-related pain (McMeekan et al., 1998; Stafford and Mellor, 2005). Behavior responses are reported to persist up to 24 to 44 h (Faulkner and Weary, 2000; Heinrich et al., 2010). Nonsteroidal antiinflammatory drugs (NSAID), including ketoprofen (Faulkner and Weary, 2000), meloxicam (Heinrich et al., 2009), carprofen (Stilwell et al., 2012), and flunixin (Glynn et al., 2013; Huber et al., 2013), reduce responses associated with pain and distress following dehorning or disbudding. To address both the initial and continued responses, a multimodal approach using analgesics that act both acutely and at length have been proposed (Stafford and Mellor, 2011).

Currently, no compounds are specifically approved to alleviate pain in livestock in the United States (Coetzee, 2013). Concerns of efficacy and administration frequency necessary to maintain analgesia concentrations have been discussed due to the number of analgesic drugs available in the United States with short elimination half-lives (Coetzee, 2011). Heinrich et al. (2010) demonstrated the administration of meloxicam, an NSAID with a long half-life in cattle, reduced both the acute response, which included reductions in cortisol concentrations, local sensitivity as well as the prolonged pain-related behaviors. As such, the use of an NSAID with a long half-life in calves may be the most ideal for pain management. Moreover, as feed is potentially the most practical and pain-free drug delivery method that can be applied in commercial livestock production systems, analgesics administered orally should be explored. Given the diversity of the pharmacologic properties of NSAID, continued investigation for optimal pain relief for disbudding and dehorning pain will benefit animal welfare.

Firocoxib is an NSAID of the coxib class with a prolonged elimination half-life and high oral bioavailability in calves (Stock et al., 2014). As a potential additional benefit, firocoxib is COX-1 sparing in both the horse and dog, which may reduce adverse effects (McCann et al., 2002, 2004). The objective of the current study was to measure the effects of firocoxib on pain and distress in preweaned dairy calves immediately before cauterity disbudding. In addition, we assessed the neuroendocrine, nociception, and physiologic responses observed following cauterity disbudding.

**MATERIALS AND METHODS**

**Animals and Housing**

Twenty Holstein calves (11 male and 9 female), 4 to 6 wk of age (mean ± SD: 32.9 ± 3.9 d), weighing 55.2 ± 5.8 kg at the time of disbudding were obtained from the Iowa State University Dairy. All calves were determined healthy following a physical examination by a veterinarian and normal findings on a complete blood count and serum chemistry. The study protocol was approved by the Institutional Animal Care and Use Committee at Iowa State University (Log#: 10–12–7443-B).

Study animals were housed in individual 3-sided closed pens (1.82 × 1.22 m) bedded with straw added daily in an enclosed facility at the Iowa State University Dairy. Calves were placed in these pens at birth and remained within the pens through the entirety of the study. While in these pens, calves had minimal physical contact with other calves, although contact to neighboring calves was possible during feeding through the one open side. Three liters of pasteurized waste milk was fed twice daily for the length of the study. To control for the variation in waste milk components, both treatment groups were given milk from the same batch pasteurization. Calves were fed grain, consisting primarily of pelleted corn, oats, molasses and protein-vitamin-mineral supplement, and offered water ad libitum. Grain was added daily at 0.45 to 0.90 kg.

Daily examinations were conducted by a veterinarian, including the monitoring of milk consumption and a subjective assessment of grain and water consumption throughout the study period.

**Study Design**

A randomized complete block design was used for this investigation, with 10 calves enrolled in each treatment group (Figure 1). The study was conducted in 2 periods. Calves were enrolled into a treatment group during period 1 and remained in that treatment group for period 2. Period 1 was conducted 2 wk before period 2. Disbudding only occurred during period 2. The purpose of period 1 was to obtain intravenous firocoxib concentrations in calves used in a subsequent pharmacokinetic analysis (Stock et al., 2014). In period 1, study animals were blocked by age and randomly assigned to receive either firocoxib (0.5 mg/kg; n = 10, male = 7) or a placebo (n = 10, male = 4). Randomization of group assignment was mediated by a computer-generated random number (Microsoft Excel 2011, Microsoft Corp.,
During period 1, calves assigned to the firocoxib group received intravenous firocoxib (Equioxx Injection, NADA 141–313, Merial LLC, Duluth, GA), whereas calves in the control group received intravenous saline via a preplaced jugular catheter followed by multiple timed blood collections. As such, calves in both treatment groups were identically handled and experienced placement and maintenance of an indwelling catheter before period 2. Following a 14-d washout period from period 1, concentrations of firocoxib were not detected at the start of period 2. Period 2 was conducted in 2 trials using 10 animals per trial which were balanced for treatment (n = 5 calves/treatment per trial). The 2 trials were initiated on consecutive days. In period 2, calves previously receiving intravenous firocoxib now received oral firocoxib (Equioxx Oral Paste, NADA 141–253, Merial LLC) and control calves received an oral whey protein placebo (Body Fortress, Bohemia, NY).

A jugular catheter was used for blood sample collection. Placement of the jugular catheter occurred approximately 12 h before the start of the investigation. A handler manually restrained the calves and the area over the jugular vein was clipped and surgically pre-
pared with alternating scrubs of 70% isopropyl alcohol and povidone iodine. The catheter site was infiltrated with 2% lidocaine injection, 1 mL subcutaneously (Hospira Inc., Lake Forest, IL). Using sterile technique, an 18 gauge × 55 mm intravenous catheter (Surflo, Terumo Medical Corp., Somerset, NJ) was inserted into the vein and sutured into the skin using #3 nylon suture (Ethilon, Ethicon, San Lorenzo, PR). An injection port (Hospira Inc.) was subsequently attached and disinfected with an alcohol swab before sample collection. Catheter patency was maintained by flushing with 3 mL of a heparin saline solution containing 3 United States Pharmacopoeial Convention units of heparin sodium/mL of saline (Heparin Sodium Injection, Baxter Healthcare, Deerfield, IL).

Calves assigned to receive firocoxib were administered a single oral dose of 0.5 mg/kg. Oral firocoxib was administered in a commercially provided dosing syringe with syringe weights obtained before and after administration to confirm the dose administered. The dose was rounded to the nearest 22.7 kg (50 pounds) as designated by the increments provided on the syringe. Using a concentration of 0.82% firocoxib, the actual mean dose of 0.5 mg/kg (range: 0.48–0.52 mg/kg) was administered to the calves as an oral paste in a dosing syringe. Control animals received an equivalent amount of a solution of saline (Heparin Sodium Injection, Baxter Healthcare, Deerfield, IL).

Blood Sample Collection

Animals were restrained during blood collection by trained handlers. Prior to sample collection, blood was aspirated and flushed back through the catheter to eliminate the heparin dilution before sample collection. Baseline samples were obtained at approximately −1.5 h from disbudding. Plasma drug concentration was confirmed as undetectable at this time. Additional blood samples were collected at 15 and 30 min and 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, and 96 h (−10 min) following disbudding. Sampling time points were determined in relation to the time drug or placebo was administered. Postdisbudding cortisol and substance P concentrations were subsequently analyzed in relation to the time of disbudding. Samples were immediately transferred to a blood collection tube with either heparin for cortisol and drug concentration or EDTA for substance P (Vacutainer, BD Diagnostics, Franklin Lakes, NJ) and stored on ice before processing. The EDTA tubes were spiked with 1 mM benzamidine (Santa Cruz Biotechnology, Santa Cruz, CA) before blood collection. Blood samples were centrifuged for 15 min at 1,500 × g at room temperature. Collected plasma was placed in cryovials and frozen at −70°C until analysis.

Cortisol

Plasma cortisol samples were determined using a commercial RIA kit (Coat-A-Count Cortisol, Siemens Medical Solutions Diagnostics, Los Angeles, CA) previously used for bovine plasma (Stilwell et al., 2008; Rialland et al., 2014). Samples were assayed in duplicate with the reported concentration equaling the average cortisol concentration between duplicates. Samples were reanalyzed if subjectively large discrepancies were noted between the duplicates. The average intra- and interassay coefficients of variation were 12.8 and 13.2%, respectively. Area under the effect curve was calculated.
using the linear trapezoidal rule as previously described (Glynn et al., 2013).

**Substance P**

Substance P (SP) concentrations were analyzed as described by Van Engen et al. (2014) using non-extracted plasma. Samples were assayed in duplicate with the reported concentration equaling the average SP concentration between duplicates. The coefficient of variation for intra-assay variability was at 7.9% and the interassay variability was calculated at 7.7%.

**Prostaglandin E2**

Ex vivo prostaglandin E2 (PGE2) synthesis inhibition was determined as described by Fraccaro et al. (2013). Blood collected from calves was placed into sterile vacuum tubes containing heparin at 4, 8, 12, 24, 48, and 72 h. The LPS obtained from Escherichia coli 0111:B4 (Sigma-Aldrich Co., St. Louis, MO) in PBS was added at 10 μg/mL to the heparinized whole blood and incubated for 24 h at 37°C. Baseline samples were incubated with and without LPS. At the end of incubation, all samples were centrifuged at 400 × g for 10 min at room temperature to obtain plasma. Methanol was added to plasma in a 1:5 plasma to methanol dilution, facilitating protein precipitation. Following centrifugation at 3,000 × g for 10 min using a non-temperature-controlled centrifuge, the supernatant was collected and stored at −80°C. A commercial PGE2 ELISA kit (Cayman Chemical, Ann Arbor, MI) previously described using methanol precipitated bovine plasma was used for determination of PGE2 concentration (Donalisio et al., 2013; Fraccaro et al., 2013). The coefficient of variation for intra-assay variability was at 8.9% and the interassay variability was calculated at 12.2%.

**Nociception and Autonomic Nervous System Responses**

Calves were restrained using a modified calf-restraining device (Easy B-Z Portable Calf Restraint, Nasco, Fort Atkinson, WI) approximately 10 min before determination of ocular temperature (OT), heart rate (HR), and mechanical nociception threshold (MNT). Additionally, following infrared thermography imaging and HR determination, calves were blindfolded for MNT to avoid withdrawal reflex based on visual cues. Baseline samples for OT, HR, and MNT were obtained on the same day for both trials, thus 16 and 21 h before initiation of the first trial and 38 and 42 h before initiation of the second trial. Baseline data for each animal were averaged for use in statistical analysis. In addition to baseline samples, response variables were collected at approximately 2, 4, 7, 8, and 24 h postdisbudding. All individuals collecting data were blinded to calf treatment group assignment.

**Infrared Thermography.** A thermography camera (FLIR SC 660, FLIR Systems, Boston, MA) with a thermal sensitivity of 0.05°C, 320 × 240 pixel display, precision >98%, was used to quantify changes in OT. The camera was internally calibrated to ambient temperature before image collection; however, additional minute adjustments to ambient temperature and humidity were used during software processing. Images were obtained from the left side of the calf, at an approximately 45° angle, and 0.5 m distance from the eye. Maximum temperature (°C) within a circumferential area of the eye, including the medial posterior palpebral border of the lower eyelid and the lacrimal cartilage, was obtained as previously described (Stewart et al., 2008). Images were analyzed using FLIR Tools (v. 4.1; FLIR Systems) following collection. At each time point, 3 images were obtained and averaged for statistical analysis.

**HR.** Heart rate was evaluated via auscultation using a stethoscope (3M, Littmann, St. Paul, MN) placed between the third and fifth intercostal space and beats were counted over a 30-s period. The value obtained was used to calculate beats per minute.

**MNT.** Pain sensitivity was measured using a handheld pressure algometer (Wagner Force Ten FDX 25 Compact Digital Force Gage, Wagner Instruments, CT) around the disbudding site, as previously described with modifications (Heinrich et al., 2010; Tapper et al., 2011; Allen et al., 2013). Two landmark locations around each horn bud as well as a control landmark were used (Figure 2). The MNT was determined as the peak applied force resulting in a withdrawal response, defined as a directed movement of the head away from the applied pressure (Tapper et al., 2011). Using a rate of approximately 1.0 kgf/s, the stimulus was applied perpendicular to the landmarks. A maximum force ceiling was established at 10 kgf. To prevent bias, the MNT output was not visualized by the individual operating the algometer. Moreover, the order of MNT landmarks and the calf side from which the pressure algometrist stood to apply the stimulus was randomized between each calf to control for potential effects on MNT determination. Each algometry site was assessed 3 times for each time point with the values averaged for the statistical analysis.

**ADG**

Animals were weighed using a Way-Pig 505 (Raytec Manufacturing, Ephrata, PA) scale 24 h before the...
disbudding (d −1), and 7 d following disbudding (d 7). Average daily gains were calculated by dividing the total weight gained between measurements and then dividing by the number of days.

**Statistical Analysis**

Analyses were performed in SAS 9.3 (SAS Institute, Cary NC) using a linear mixed effects model with repeated measures. Data obtained from response variables including MNT, cortisol, SP, and PGE₂ were log-transformed for normality. Baseline values were used as covariates for all variables analyzed. The fixed effects were treatment (firocoxib, placebo), time, and the interaction between treatment and time. The effect of sex was tested in the statistical model and removed to improve the fit of the statistical analysis when no effect was observed (P > 0.1). Trial was a random effect and calf was the subject of repeated measures. F-tests were used to test the significance of main effects and interactions. If significant overall differences were identified among levels of a factor, pairwise comparisons were performed using Tukey’s t-tests. Additionally, paired t-tests were performed to test the differences between response variable baselines as well as LPS-stimulated and unstimulated baseline ex vivo PGE₂ concentrations. Statistical significance was designated as a P-value <0.05; P-values ranging between 0.05 and 0.1 were discussed as a tendency to significance.

**RESULTS**

No animals required rescue analgesia or were removed throughout the course of the study. There was no effect of sex observed on any measured responses (P > 0.1). As such, sex was removed from the statistical analysis.

**Cortisol**

Mean cortisol concentrations were not significantly different between treatment groups (P = 0.80) (Table 1). Both a time effect (P < 0.0001) and time × treatment interaction (P = 0.0076) were observed in cortisol concentrations throughout the 96-h sampling period (Table 1). Initially, cortisol concentrations increased following disbudding, peaking, on average, at approximately 20 min following the hot-iron procedure. Mean cortisol concentrations decreased thereafter. At 50 min postdisbudding, placebo-treated calves had a significant reduction (2.2 nmol/L) compared with firocoxib-treated calves (P = 0.012; Figure 3a). In contrast, at approximately 48 h postdisbudding, a significant increase in cortisol concentrations was observed in placebo-treated calves compared with firocoxib-treated calves (22.8 ± 2.9 vs. 11.5 ± 1.7 nmol/L; P = 0.0006; Figure 3b). Furthermore, the integrated cortisol response calculated as the area under the effect curve tended to be reduced in firocoxib-treated calves (1,157.0 ± 179 vs. 1,610.8 ± 255 nmol.h/L; P = 0.093; Figure 4).

**SP**

Mean ± standard error SP concentrations in firocoxib-treated calves (22.7 ± 0.7 pg/mL) were not significantly different compared with calves receiving placebo.
Additionally, no effect of time ($P = 0.42$) or a time $\times$ treatment interaction ($P = 0.66$) were observed for the 96-h sampling period.

**PGE$_2$**

Due to laboratory error in sample processing, samples collected and processed for ex vivo PGE$_2$ synthesis at 4 and 8 h were removed from the statistical analysis. An overall treatment effect was observed with PGE$_2$ synthesis reduced in firocoxib-treated calves ($770.4 \pm 97.9$ pg/mL) compared with placebo treatment ($1,249.7 \pm 105.5$ pg/mL; $P = 0.0012$). Moreover, an effect of time ($P < 0.0001$) and a time $\times$ treatment interaction ($P = 0.019$) was observed. Firocoxib treatment resulting in decreased PGE$_2$ concentrations at 12 ($P < 0.0001$), 24 ($P = 0.0073$), and 48 h ($P = 0.0005$; Figure 5). At 72 h, no difference was observed between treatment groups ($P = 0.34$). Baseline LPS-stimulated blood resulted in a significant increase in PGE$_2$ concentrations compared with non-LPS stimulated control samples for both treatment groups ($P < 0.0001$).
Infrared Thermography

Mean OT were not significant between treatment groups (P = 0.85). A time effect was observed in OT response following disbudding (P < 0.0001; Table 1; Figure 6). For both firocoxib- and placebo-treated calves, OT numerically decreased 0.12 ± 0.10°C and 0.15 ± 0.10°C from 2 to 4 h following disbudding. Ocular temperature significantly increased thereafter, with a mean peak temperature recorded at 8 h for both treatment groups. Additionally, a significant temperature reduction was observed 24 h postdisbudding for both treatment groups in comparison to all previous time points, including baseline (P < 0.0001). No interaction between time and treatment (P = 0.98) was observed.

HR

No treatment effects were observed between treatment groups (P = 0.96). A time effect was observed with HR altered following disbudding (P = 0.019; Table 1). There was no time × treatment interaction (P = 0.16). Interestingly, HR significantly decreased in firocoxib-treated calves 24 h postdisbudding compared with both 7 (P = 0.021) and 8 h (P = 0.0030). This response was not observed in placebo-treated calves.

MNT

Numerically, firocoxib-treated calves tolerated more pressure around the horn bud area (1.15 ± 0.16 kg) compared with placebo-treated controls (0.96 ± 0.14); however, this effect was not significant (P = 0.56; Table 1). Overall, a time effect on MNT was observed (P < 0.0001). Postdisbudding measurements were reduced below baseline values throughout the 24-h testing period (Figure 7). There was no evidence of an interaction of time and treatment (P = 0.84).

ADG

Initial weights were determined the day before disbudding. The mean weights (LSM ± SE) before disbudding were 55.5 ± 1.7 and 55.0 ± 2.0 kg for the firocoxib and placebo groups, respectively. All calves gained weight throughout the study period with final mean weights equaling 59.1 ± 2.0 and 59.0 ± 2.4 kg for firocoxib- and placebo-treated groups, respectively. There was no difference in ADG for firocoxib- and placebo-treated calves (0.5 ± 0.1 vs. 0.5 ± 0.1 kg; P = 0.61; Table 1).

DISCUSSION

Cautery disbudding in calves resulted in an increased cortisol concentrations, as well as an increased sensitivity as determined by MNT. Moreover, changes in nociception persisted throughout the 24-h study period where local pressure tolerated by calves did not return to baseline values. Firocoxib administration did not alter the tested responses observed between treatment groups over the initial 24-h period; however, cortisol concentrations between treatment groups diverged at 48 h postdisbudding, where firocoxib-treated calves had reduced cortisol concentration. Furthermore, the integrated cortisol response tended to be decreased in firocoxib-treated animals compared with calves administered a placebo. These differences observed following the initial 24 h could be attributed to the administration of an NSAID with persistent concentrations;
however, additional study is required to determine its long-term effects.

Historically, perioperative analgesics administered to calves before dehorning or disbudding have used NSAID that have data, both public and proprietary, to support an anti-inflammatory claim (Stilwell et al., 2009; Duffield et al., 2010; Heinrich et al., 2010; Glynn et al., 2013). This aids in the dose determination for an investigation into its analgesic potential. However, for our study, no information was publicly available concerning the analgesic use of firocoxib in preweaned calves. As such, the dose of 0.5 mg/kg used in our study was based on pharmacokinetic information available in the horse labeled for use at 0.1 mg/kg. The equine-approved dose demonstrated analgesia in naturally occurring lameness following multiple daily doses (Orsini et al., 2012). More recently, it has been suggested to use a loading dose in horses to achieve steady state drug concentrations more quickly (Cox et al., 2013). As a result, effective concentrations may be reached more rapidly. In our study, a one-time dose administration was anticipated for the practical application of this analgesic in calves. As such, the increased dose compared with the dose used in horses was chosen to best provide potentially effective concentration of drug as well as remain practical in its administration. However, we cannot rule out that differences in pharmacokinetic properties of firocoxib between species may also have contributed to the differences in analgesic response.

A primary property of most NSAID is reducing eicosanoid production via inhibition of cyclooxygenase isoenzymes. Therefore, a potential method of dose evaluation involves an investigation into a drug’s ability to decrease PGE2 concentrations, a major eicosanoid metabolite associated with inflammation and nociception threshold reduction (Basbaum et al., 2009). An investigation of the PGE2 in our study indicated the administered dose reduced ex vivo PGE2 synthesis from 12 to 48 h compared with placebo-treated controls. Although further evaluation is required to determine concentrations necessary to achieve analgesia, it should be noted that the administration of firocoxib at the study dose attained concentrations necessary to significantly inhibit ex vivo PGE2 concentrations for at least 2 d. This is similar to the findings of Allen et al. (2013), who observed a suppression of ex vivo PGE2 synthesis for 48 h after oral administration of meloxicam at 1 mg/kg at the time of disbudding.

During the first 24 h, cortisol concentrations were similar over time for both treatment groups. Although placebo-treated calves had decreased cortisol concentrations 50 min postdisbudding, the effect size was small and the response may be confounded with the desensitization of the local anesthetic. The initial increase in cortisol concentrations peaking at 20 min postdisbudding and returning to pretreatment levels within approximately 1 h is similar to that presented in previous literature (Stafford and Mellor, 2005). Moreover, in combination with a local anesthetic, the use of cautery following amputation dehorning nearly eliminated the cortisol response for 24 (Sutherland et al., 2002) to 36 h (Sylvester et al., 1998) after dehorning. It should be noted that in the former study, both lidocaine and then bupivacaine 2 h later were used to provide local anesthesia for a duration of 5 h (Sutherland et al., 2002). This significantly reduced cortisol response has also been observed in lambs undergoing cautery tail docking, suggesting that cautery may attenuate the nociception signal below the pain threshold for transmission (Lester et al., 1991; Stafford and Mellor, 2011). An attenuation of this systemic response using cautery may contradict the MNT profile observed in our study; however, the pressure algometer evaluates local sensitivity surrounding the horn bud and may not reflect a systemic distress response.

After 24 h, the mean cortisol response diverges between the 2 treatment groups with placebo-treated calves increasing in cortisol with a peak at approximately 48 h postdisbudding. Using cortisol as a measure of distress, firocoxib administration may have mitigated the distress associated with disbudding. This statement is further supported with evidence suggesting that firocoxib concentrations between 24 and 48 h continued to reduce ex vivo PGE2 synthesis. Prolonged changes in cortisol associated with dehorning and disbudding have been difficult to routinely characterize. Morisse et al. (1995) reported elevated cortisol concentrations 24 h postdehorning compared with control calves 8 wk of age. More recently, in 8- to 10-wk-old calves, Allen et al. (2013) reported a mean increased cortisol concentration from 96 to 120 h in calves treated with meloxicam 12 h before dehorning. Calf behavior, including ear flicks, grazing time, and ruminating responses, provide further support that disbudding and dehorning pain may continue for 24 to 48 h (Faulkner and Weary, 2000; Stafford and Mellor, 2005; Heinrich et al., 2010). These changes in cortisol and behavior may be mediated by an increased inflammatory response evidenced by an increased haptoglobin concentration reported 24 to 48 h following amputation dehorning in 6-mo-old calves (Glynn et al., 2013). In contrast, other studies report cortisol concentrations return to and are maintained at baseline values 24 (Sutherland et al., 2002) to 36 h (Sylvester et al., 1998) in 3- to 4- or 5- to 6-mo-old calves, respectively, that were scoop dehorned followed by wound cautereization.

Substance P, a neuropeptide previously indicated as a pain biomarker in cattle, was not different between
treatment groups (Coetzee et al., 2008). Moreover, no significant change in SP over time was noted. These data differ from other investigations evaluating SP following dehorning. In 8- to 10-wk-old calves, Allen et al. (2013) reported a time by treatment interaction with a significant increase in SP concentrations at 120 h after cautery dehorning in control animals compared with those receiving meloxicam. Furthermore, Coetzee et al. (2012) reported a significant reduction in SP following administration of an NSAID, meloxicam, following scoop dehorning in 4- to 5-mo-old calves. Differences in the length of sample collection time, disbudding or dehorning method, and analytical method used to measure SP may be the reason for the observed disagreement with the present study. Moreover, age differences in these study populations may significantly influence SP response. Dockweiler et al. (2013) reported a decreased response in SP in cattle castrated at ≤8 wk in comparison to cattle ≥6 mo; the authors suggest a reduced pain response or different physiological parameters contributing to this difference. Coupled with data collected in the present study, SP may be a poor indicator of pain in young animals. Both in our study and demonstrated by Allen et al. (2013), no significant differences in SP were reported for the first 96 h following dehorning. As SP release is thought to be associated with pain, evidence from our study support the hypothesis that cautery may destroy nearby nociceptors necessary to reach pain thresholds needed for central hyperalgesia transmission (Sylvestre et al., 1998; Sutherland et al., 2002). It should be noted this hypothesis was derived from the evaluation of the cortisol response following local anesthesia and scoop then cautery dehorned calves greater than 3 mo of age.

Local nociception changes persisted for 24 h in both treatment groups as observed in the MNT profiles such that nociception thresholds did not return to baseline values during the measured response period. This duration of sensitivity appears to be consistent with other reports indicating a prolonged response following dehorning or disbudding based on behavior (Faulkner and Weary, 2000; Heinrich et al., 2010) and on nociceptive thresholds (Taper et al., 2011). Average MNT profiles were similar between treatment groups, suggesting firocoxib did not significantly demonstrate antinociceptive effects over the 24-h investigation period postdisbudding. This response differs from MNT values reported following perioroperative administration of meloxicam (Heinrich et al., 2010) and ethanol as a local anesthetic (Taper et al., 2011). Repeated handling for data collection may have heightened the avoidance responses of calves in the current study when compared with the nociception threshold testing performed at one time point by Heinrich and colleagues (2010). Reduction in subtle dehorning pain-related behaviors, such as ear flicking and head rubbing, have been associated with perioroperative administration of meloxicam (Heinrich et al., 2010), ketoprofen (Faulkner and Weary, 2000; Duffield et al., 2010), and carprofen (Stilwell et al., 2012), but this was not assessed in the current study.

Changes to the autonomic nervous system response, including HR and OT, were observed after disbudding. Although not statistically significant, the decrease in ocular temperature observed between 2 and 4 h most likely was due to the loss of the local anesthetic effect, as previously described by Stewart et al. (2009). The significant decrease of ocular temperature at 24 h for both treatment groups may also suggest a continued autonomic nervous system response caused by disbudding; however, changes in temperatures due to diurnal core temperature changes or environment cannot be eliminated (Vickers et al., 2010; Church et al., 2014). Although prior studies have indicated a reduced volatility of the autonomic nervous system with the use of an NSAID following cautery disbudding or dehorning (Stewart et al., 2009; Heinrich et al., 2009; Coetzee et al., 2012), no treatment differences were observed over the 24-h sampling period for both OT and HR in the present study. Animals were frequently handled before disbudding to help reduce response variations associated with sample collection. However, responses of the autonomic nervous system may vary according to novel stimuli and exertion; frequent handling required for blood collection may result in elevated responses regardless of the administration of an analgesic. As no analgesic effects were noted in any response variable during the first 24 h, firocoxib administration at the study dose may be ineffective at managing the acute nociception and distress associated with cautery disbudding.

**CONCLUSIONS**

Evidence provided in the current study indicates cautery disbudding resulted in changes in nociception and cortisol concentrations. The study dose of firocoxib was sufficient to effectively reduce ex vivo PGE2 synthesis; however, determination of analgesic concentrations require further investigation, as no significant differences in analgesic response variables were observed in the first 24 h. As such, the relationship between response variables and ex vivo PGE2 inhibition requires further exploration. Overall, a one-time oral administration of firocoxib reduced cortisol concentrations at 48 h and contributed to the attenuated integrated concentration of plasma cortisol; however, the acute response (<24 h) as measured by OT, HR, MNT, cortisol, and SP was unaffected by treatment. Further research is needed.
to determine the significance of the prolonged cortisol response following disbudding and the potential for firocoxib to ameliorate this effect.

ACKNOWLEDGMENTS

Supported by the Pharmacology Analytical Support Team (PhAST) in the College of Veterinary Medicine at Iowa State University. The authors thank the following individuals who provided invaluable support to the project: Larry Wulf, Jay Lawrence, Jackie Peterson, Travis Vlietstra, Ben Schmidt, Jessie Juarez, Chris Sievers, and Josh Ydstie.

REFERENCES


EFFECTS OF FIROCOXIB DURING DISBUDDING


